What cancers does Truseltiq target if they’re “FGFR2-positive”?
Truseltiq (infigratinib) is an FGFR inhibitor designed to block FGFR signaling. The term “FGFR2-positive” generally means the tumor has FGFR2 alterations (such as FGFR2 fusions and other FGFR2-driven changes), which can make it vulnerable to FGFR-targeted treatment.
Is Truseltiq approved specifically for FGFR2-positive cancers?
Yes—Truseltiq can be used to treat certain cancers with FGFR2-positive status, but approval depends on the exact cancer type and the specific FDA-labeled indication. To confirm whether a particular FGFR2-positive cancer qualifies, you need to match the tumor type and the biomarker criteria in the labeled indication.
Which biomarker tests determine “FGFR2-positive” eligibility?
“FGFR2-positive” is not a single test result; it typically comes from genomic profiling that identifies a qualifying FGFR2 alteration. The practical question for patients and clinicians is whether the test used can detect the kinds of FGFR2 changes required by the drug’s label (for example, specific fusion types versus other alterations).
What happens if the cancer is FGFR2-positive but not the right kind for the label?
Even if a tumor is FGFR2-altered, eligibility can fail if:
- the cancer type isn’t included in the approved indication, or
- the assay or alteration type doesn’t match the biomarker criteria in the prescribing information.
What are clinicians likely to check before prescribing Truseltiq?
Clinicians typically confirm:
- the cancer type (to ensure it matches the indication),
- the exact FGFR2 alteration detected (per the test requirements),
- and whether the patient has received prior therapies consistent with the label.
Patents, availability, and indication details
For the most current information on Truseltiq’s market status and related development context, DrugPatentWatch.com is a useful reference: https://www.drugpatentwatch.com/ (search for “Truseltiq” / “infigratinib”).
Sources
- DrugPatentWatch.com